vs
安捷伦科技（A）与Encompass Health Corp（EHC）财务数据对比。点击上方公司名可切换其他公司
安捷伦科技的季度营收约是Encompass Health Corp的1.2倍（$1.8B vs $1.5B）。安捷伦科技净利率更高（17.0% vs 9.5%，领先7.5%）。Encompass Health Corp同比增速更快（9.9% vs 7.0%）。安捷伦科技自由现金流更多（$175.0M vs $116.7M）。过去两年Encompass Health Corp的营收复合增速更高（8.3% vs 6.9%）
安捷伦科技是全球知名的生命科学、诊断与应用化学领域解决方案提供商，旗下生命科学与应用市场业务板块提供液相色谱系统及组件、液相色谱质谱联用系统、气相色谱设备、电感耦合等离子体质谱仪、原子吸收仪等多种分析检测仪器，服务全球各领域客户。
Encompass Health Corp前身为Amcare及HealthSouth，总部位于美国阿拉巴马州伯明翰，是美国规模最大的住院康复服务提供商，在39个州及波多黎各拥有173家住院康复医院，为中风、神经系统疾病、心肺病症、脑损伤等患者提供专业康复诊疗服务。
A vs EHC — 直观对比
营收规模更大
A
是对方的1.2倍
$1.5B
营收增速更快
EHC
高出3.0%
7.0%
净利率更高
A
高出7.5%
9.5%
自由现金流更多
A
多$58.3M
$116.7M
两年增速更快
EHC
近两年复合增速
6.9%
损益表 — Q1 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.8B | $1.5B |
| 净利润 | $305.0M | $146.1M |
| 毛利率 | 52.6% | — |
| 营业利润率 | 19.6% | 16.7% |
| 净利率 | 17.0% | 9.5% |
| 营收同比 | 7.0% | 9.9% |
| 净利润同比 | -4.1% | 20.8% |
| 每股收益（稀释后） | $1.07 | $1.43 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AEHC
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.9B | $1.5B | ||
| Q3 25 | $1.7B | $1.5B | ||
| Q2 25 | $1.7B | $1.5B | ||
| Q1 25 | $1.7B | $1.5B | ||
| Q4 24 | $1.7B | $1.4B | ||
| Q3 24 | $1.6B | $1.4B | ||
| Q2 24 | $1.6B | $1.3B |
净利润AEHC
| Q1 26 | $305.0M | — | ||
| Q4 25 | $434.0M | $146.1M | ||
| Q3 25 | $336.0M | $126.5M | ||
| Q2 25 | $215.0M | $142.1M | ||
| Q1 25 | $318.0M | $151.5M | ||
| Q4 24 | $351.0M | $120.9M | ||
| Q3 24 | $282.0M | $108.2M | ||
| Q2 24 | $308.0M | $114.1M |
毛利率AEHC
| Q1 26 | 52.6% | — | ||
| Q4 25 | 53.2% | — | ||
| Q3 25 | 51.1% | — | ||
| Q2 25 | 51.9% | — | ||
| Q1 25 | 53.5% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 54.2% | — | ||
| Q2 24 | 54.4% | — |
营业利润率AEHC
| Q1 26 | 19.6% | — | ||
| Q4 25 | 23.8% | 16.7% | ||
| Q3 25 | 20.7% | 14.9% | ||
| Q2 25 | 18.0% | 16.2% | ||
| Q1 25 | 22.4% | 16.4% | ||
| Q4 24 | 24.0% | 14.3% | ||
| Q3 24 | 21.1% | 13.6% | ||
| Q2 24 | 23.1% | 14.3% |
净利率AEHC
| Q1 26 | 17.0% | — | ||
| Q4 25 | 23.3% | 9.5% | ||
| Q3 25 | 19.3% | 8.6% | ||
| Q2 25 | 12.9% | 9.7% | ||
| Q1 25 | 18.9% | 10.4% | ||
| Q4 24 | 20.6% | 8.6% | ||
| Q3 24 | 17.9% | 8.0% | ||
| Q2 24 | 19.6% | 8.8% |
每股收益（稀释后）AEHC
| Q1 26 | $1.07 | — | ||
| Q4 25 | $1.53 | $1.43 | ||
| Q3 25 | $1.18 | $1.24 | ||
| Q2 25 | $0.75 | $1.39 | ||
| Q1 25 | $1.11 | $1.48 | ||
| Q4 24 | $1.23 | $1.18 | ||
| Q3 24 | $0.97 | $1.06 | ||
| Q2 24 | $1.05 | $1.12 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.8B | $72.2M |
| 总债务越低越好 | $3.0B | $2.4B |
| 股东权益账面价值 | $6.9B | $2.4B |
| 总资产 | $12.8B | $7.1B |
| 负债/权益比越低杠杆越低 | 0.44× | 1.00× |
8季度趋势，按日历期对齐
现金及短期投资AEHC
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.8B | $72.2M | ||
| Q3 25 | $1.5B | $48.7M | ||
| Q2 25 | $1.5B | $99.1M | ||
| Q1 25 | $1.5B | $95.8M | ||
| Q4 24 | $1.3B | $85.4M | ||
| Q3 24 | $1.8B | $147.8M | ||
| Q2 24 | $1.7B | $154.4M |
总债务AEHC
| Q1 26 | $3.0B | — | ||
| Q4 25 | $3.0B | $2.4B | ||
| Q3 25 | $3.4B | $2.4B | ||
| Q2 25 | $3.3B | $2.3B | ||
| Q1 25 | $3.3B | $2.3B | ||
| Q4 24 | $3.3B | $2.4B | ||
| Q3 24 | $2.1B | $2.3B | ||
| Q2 24 | $2.1B | $2.7B |
股东权益AEHC
| Q1 26 | $6.9B | — | ||
| Q4 25 | $6.7B | $2.4B | ||
| Q3 25 | $6.4B | $2.4B | ||
| Q2 25 | $6.1B | $2.3B | ||
| Q1 25 | $6.0B | $2.2B | ||
| Q4 24 | $5.9B | $2.1B | ||
| Q3 24 | $5.9B | $2.0B | ||
| Q2 24 | $6.2B | $1.8B |
总资产AEHC
| Q1 26 | $12.8B | — | ||
| Q4 25 | $12.7B | $7.1B | ||
| Q3 25 | $12.2B | $6.9B | ||
| Q2 25 | $12.2B | $6.8B | ||
| Q1 25 | $11.9B | $6.6B | ||
| Q4 24 | $11.8B | $6.5B | ||
| Q3 24 | $11.0B | $6.5B | ||
| Q2 24 | $10.9B | $6.4B |
负债/权益比AEHC
| Q1 26 | 0.44× | — | ||
| Q4 25 | 0.45× | 1.00× | ||
| Q3 25 | 0.53× | 1.01× | ||
| Q2 25 | 0.55× | 1.02× | ||
| Q1 25 | 0.56× | 1.08× | ||
| Q4 24 | 0.57× | 1.14× | ||
| Q3 24 | 0.36× | 1.20× | ||
| Q2 24 | 0.34× | 1.46× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $268.0M | $346.0M |
| 自由现金流经营现金流 - 资本支出 | $175.0M | $116.7M |
| 自由现金流率自由现金流/营收 | 9.7% | 7.6% |
| 资本支出强度资本支出/营收 | 5.2% | 14.8% |
| 现金转化率经营现金流/净利润 | 0.88× | 2.37× |
| 过去12个月自由现金流最近4个季度 | $993.0M | $439.2M |
8季度趋势，按日历期对齐
经营现金流AEHC
| Q1 26 | $268.0M | — | ||
| Q4 25 | $545.0M | $346.0M | ||
| Q3 25 | $362.0M | $270.8M | ||
| Q2 25 | $221.0M | $270.2M | ||
| Q1 25 | $431.0M | $288.6M | ||
| Q4 24 | $481.0M | $278.8M | ||
| Q3 24 | $452.0M | $267.8M | ||
| Q2 24 | $333.0M | $217.4M |
自由现金流AEHC
| Q1 26 | $175.0M | — | ||
| Q4 25 | $452.0M | $116.7M | ||
| Q3 25 | $259.0M | $83.7M | ||
| Q2 25 | $107.0M | $113.3M | ||
| Q1 25 | $334.0M | $125.5M | ||
| Q4 24 | $388.0M | $80.1M | ||
| Q3 24 | $360.0M | $120.3M | ||
| Q2 24 | $230.0M | $60.5M |
自由现金流率AEHC
| Q1 26 | 9.7% | — | ||
| Q4 25 | 24.3% | 7.6% | ||
| Q3 25 | 14.9% | 5.7% | ||
| Q2 25 | 6.4% | 7.8% | ||
| Q1 25 | 19.9% | 8.6% | ||
| Q4 24 | 22.8% | 5.7% | ||
| Q3 24 | 22.8% | 8.9% | ||
| Q2 24 | 14.6% | 4.6% |
资本支出强度AEHC
| Q1 26 | 5.2% | — | ||
| Q4 25 | 5.0% | 14.8% | ||
| Q3 25 | 5.9% | 12.7% | ||
| Q2 25 | 6.8% | 10.8% | ||
| Q1 25 | 5.8% | 11.2% | ||
| Q4 24 | 5.5% | 14.1% | ||
| Q3 24 | 5.8% | 10.9% | ||
| Q2 24 | 6.5% | 12.1% |
现金转化率AEHC
| Q1 26 | 0.88× | — | ||
| Q4 25 | 1.26× | 2.37× | ||
| Q3 25 | 1.08× | 2.14× | ||
| Q2 25 | 1.03× | 1.90× | ||
| Q1 25 | 1.36× | 1.90× | ||
| Q4 24 | 1.37× | 2.31× | ||
| Q3 24 | 1.60× | 2.48× | ||
| Q2 24 | 1.08× | 1.91× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
A
| Service Other | $525.0M | 29% |
| Chemicaland Energy Market | $422.0M | 23% |
| Agilent Cross Lab | $273.0M | 15% |
| Environmentaland Forensics Market | $177.0M | 10% |
| Food Market | $166.0M | 9% |
| Academiaand Government Market | $130.0M | 7% |
| Applied Markets | $98.0M | 5% |
EHC
| Medicare | $1.0B | 66% |
| Medicare Advantage | $243.1M | 16% |
| Managed Care | $160.7M | 10% |
| Medicaid | $47.0M | 3% |
| Other Income Source | $44.8M | 3% |
| Other Thirdparty Payors | $11.2M | 1% |
| Workers Compensation | $7.6M | 0% |
| Patients | $4.6M | 0% |
